CD8A and melanoma: Unfortunately, a pegylated form of IL-2, bempegaldesleukin, which is thought to preferentially bind to the beta/gamma chains of the IL-2 receptor and expand predominantly CD8+ T effector cells, has shown no efficacy in first-line stage IV melanoma.